See more : Perfect Corp. (PERF) Income Statement Analysis – Financial Results
Complete financial analysis of Guardion Health Sciences, Inc. (GHSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardion Health Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sai Silks (Kalamandir) Limited (KALAMANDIR.BO) Income Statement Analysis – Financial Results
- PHAXIAM Therapeutics S.A. (PHXM) Income Statement Analysis – Financial Results
- Woluwe Extension SA (WOLE.BR) Income Statement Analysis – Financial Results
- Flowing Cloud Technology Ltd (6610.HK) Income Statement Analysis – Financial Results
- Shenzhen Qingyi Photomask Limited (688138.SS) Income Statement Analysis – Financial Results
Guardion Health Sciences, Inc. (GHSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.guardionhealth.com
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.25M | 11.05M | 7.23M | 1.89M | 902.94K | 942.15K | 437.35K | 141.03K | 112.81K | 164.58K | 260.36K |
| Cost of Revenue | 6.85M | 6.53M | 4.12M | 1.95M | 341.32K | 398.18K | 175.47K | 75.70K | 50.07K | 145.53K | 168.88K |
| Gross Profit | 5.39M | 4.52M | 3.11M | -56.79K | 561.62K | 543.97K | 261.88K | 65.33K | 62.74K | 19.05K | 91.48K |
| Gross Profit Ratio | 44.04% | 40.91% | 43.00% | -3.01% | 62.20% | 57.74% | 59.88% | 46.32% | 55.61% | 11.58% | 35.14% |
| Research & Development | 150.68K | 193.80K | 64.36K | 160.98K | 194.31K | 231.85K | 259.46K | 64.03K | 401.91K | 43.44K | 259.79K |
| General & Administrative | 7.48M | 9.58M | 11.20M | 6.83M | 7.43M | 4.93M | 4.68M | 3.31M | 5.61M | 638.00K | 616.70K |
| Selling & Marketing | 1.70M | 2.07M | 2.32M | 1.45M | 1.87M | 1.52M | 599.93K | 389.11K | 180.13K | 46.77K | 51.60K |
| SG&A | 9.19M | 11.65M | 13.53M | 8.28M | 9.30M | 6.46M | 5.28M | 3.70M | 5.79M | 684.77K | 668.30K |
| Other Expenses | 394.55K | 3.57M | 10.14M | 0.00 | 1.22M | 0.00 | 0.00 | 174.04K | -1.70M | 0.00 | 0.00 |
| Operating Expenses | 9.73M | 11.84M | 13.59M | 8.45M | 9.50M | 6.69M | 5.54M | 3.76M | 6.19M | 728.21K | 928.09K |
| Cost & Expenses | 16.58M | 18.37M | 17.72M | 10.39M | 9.84M | 7.09M | 5.72M | 3.84M | 6.24M | 873.74K | 1.10M |
| Interest Income | 379.52K | 152.57K | 1.80K | 7.27K | 258.37K | 0.00 | 0.00 | 0.00 | 0.00 | 611.34K | 406.07K |
| Interest Expense | 0.00 | 15.35M | 0.00 | 7.27K | 258.37K | 2.29K | 23.73K | 1.10M | 752.95K | 0.00 | 0.00 |
| Depreciation & Amortization | 19.42K | 1.25M | 910.37K | 219.60K | 625.79K | 295.67K | 118.82K | 60.13K | 53.74K | 43.23K | 8.84K |
| EBITDA | -3.92M | -6.07M | -9.70M | -8.34M | -9.99M | -7.47M | -5.16M | -4.58M | -8.03M | -665.92K | -827.77K |
| EBITDA Ratio | -32.02% | 15.22% | -132.36% | -438.27% | -966.13% | -620.71% | -1,180.44% | -2,578.07% | -6,892.95% | -404.61% | -317.94% |
| Operating Income | -4.34M | 432.68K | -10.48M | -8.55M | -8.93M | -6.14M | -5.28M | -3.95M | -6.39M | -709.15K | -836.61K |
| Operating Income Ratio | -35.40% | 3.92% | -144.94% | -452.51% | -989.37% | -652.09% | -1,207.60% | -2,797.79% | -5,663.22% | -430.88% | -321.33% |
| Total Other Income/Expenses | 4.49M | 2.50M | 1.80K | -19.93K | -381.37K | -1.62M | -23.73K | -1.80M | -2.45M | -611.34K | -406.07K |
| Income Before Tax | 158.03K | -14.92M | -24.75M | -8.57M | -10.88M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Income Before Tax Ratio | 1.29% | -135.05% | -342.11% | -453.56% | -1,204.77% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| Income Tax Expense | 0.00 | 15.35M | 672.79K | 7.27K | 258.37K | -1.62M | 0.00 | 1.10M | -946.66K | 0.00 | 0.00 |
| Net Income | 158.03K | -30.28M | -24.75M | -8.58M | -11.14M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
| Net Income Ratio | 1.29% | -274.01% | -342.11% | -453.95% | -1,233.38% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
| EPS | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.39 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| EPS Diluted | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.09 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
| Weighted Avg Shares Out | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.70K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
| Weighted Avg Shares Out (Dil) | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.91K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023
7 Penny Stocks That Actually Have Buy Ratings
7 Undervalued Penny Stocks to Buy for Massive Gains
Best Penny Stocks to Watch as the Market Turns Bullish Today
Guardion Health Sciences to Present at the Planet MicroCap Showcase 2022
4 Top Penny Stocks To Buy For Under $1 This Week
Trading Penny Stocks? Top Stock Market News for March 2nd, 2022
Hot Penny Stocks To Buy For Under $1 In March 2022
GHSI Stock: 12 Things to Know About Guardion Health Science as Shares Rocket
Source: https://incomestatements.info
Category: Stock Reports